-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Telitacicept in Relapsing Remitting Multiple Sclerosis (RRMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Telitacicept in Relapsing Remitting Multiple Sclerosis (RRMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Telitacicept in Relapsing Remitting Multiple Sclerosis (RRMS) Drug Details:Telitacicept (Tai'...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eftilagimod alfa in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eftilagimod alfa in Hepatocellular Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eftilagimod alfa in Hepatocellular Carcinoma Drug Details: Eftilagimod alfa (IMP-321, EDP-202)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eribulin Mesylate in Primitive Neuroectodermal Tumor (PNET)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eribulin Mesylate in Primitive Neuroectodermal Tumor (PNET) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eribulin mesylate in Primitive Neuroectodermal Tumor (PNET) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab in Laryngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Laryngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab in Laryngeal Cancer Drug Details: Pembrolizumab (Keytruda) is an antineoplastic immunomodulating...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – IOA-244
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry IOA-244 Drug Details IOA-244 is under development for the treatment of solid tumors including...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – IOA-289
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry IOA-289 Drug Details IOA-289 is under development for the treatment of solid tumors, idiopathic...